| Description : |
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize as many as 25% of commonly prescribed drugs. Its substrates include antidepressants, antipsychotics, analgesics and antitussives, beta adrenergic blocking agents, antiarrythmics and antiemetics. The gene is highly polymorphic in the human population; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzyme's substrates. Some individuals with the poor metabolizer phenotype have no functional protein since they carry 2 null alleles whereas in other individuals the gene is absent. This gene can vary in copy number and individuals with the ultrarapid metabolizer phenotype can have 3 or more active copies of the gene. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
| Source : |
Sf9 insect cells |
| Species : |
Human |
| Form : |
LKM-1 is supplied in 17mM HEPES pH-7.5, 425mM NaCl, 1mM DTT, 1% Triton X-100 and 15% glycerol. |
| Molecular Mass : |
60 kDa |
| Purity : |
95% |
| Applications : |
Western-Blot with monoclonal anti-LKM-1 antibody and anti-LKM-1 autoantibody-positive sample. |
| Usage : |
For Research Use Only. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals. |
| Stability : |
Store at 4 centigrade if entire vial will be used within 2-4 weeks.
Store, frozen at -20 centigrade for longer periods of time.
Avoid multiple freeze-thaw cycles. |
| Concentration : |
0.35-0.6 µg/ml |
| tmpcolum67 : |
cytochrome P450 family 2 subfamily D member 6 |
